Citi Downgrades SUMITOMO PHARMA CO LTD(DNPUF.US) to Sell Rating, Raises Target Price to $3

Futu NewsOct 29 03:31 · Ratings

Jefferies Maintains SUMITOMO PHARMA CO LTD(DNPUF.US) With Hold Rating, Raises Target Price to $5.2

Jefferies analyst Stephen Barker maintains $SUMITOMO PHARMA CO LTD(DNPUF.US)$ with a hold rating, and adjusts the target price from $2.86 to $5.18.According to TipRanks data, the analyst has a

Futu NewsAug 27 20:33 · Ratings

J.P. Morgan Initiates SUMITOMO PHARMA CO LTD(DNPUF.US) With Hold Rating, Announces Target Price $3.39

J.P. Morgan analyst Naomi Kumagai initiates coverage on $SUMITOMO PHARMA CO LTD(DNPUF.US)$ with a hold rating, and sets the target price at $3.41.According to TipRanks data, the analyst has a

Futu NewsAug 16 17:34 · Ratings

Citi Initiates SUMITOMO PHARMA CO LTD(DNPUF.US) With Hold Rating, Announces Target Price $3.14

Citi analyst Hidemaru Yamaguchi initiates coverage on $SUMITOMO PHARMA CO LTD(DNPUF.US)$ with a hold rating, and sets the target price at $3.14.According to TipRanks data, the analyst has a success

Futu NewsAug 8 22:35 · Ratings

Sumitomo Pharma --- sharp decline, reportedly showing a policy to reduce the development of new pharmaceuticals

A sharp decline. At the management briefing held the day before, it is reported that they indicated a policy to drastically reduce the development of new pharmaceuticals. Research and development expenses for the fiscal year ending 25/3 are likely to be reduced 45% from the previous fiscal year to 50 billion yen. While expanding sales of the 3 chemicals positioned as core products, it seems that they are aiming to recover the surplus by proceeding with cost reduction. It seems to be leading to a negative view that the reduction in research and development expenses will narrow the room for future growth.

Fisco JapanMay 2 11:47